Product Description
Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Belinostat)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Brazil | Chile | Greece | Peru | United States
Approved Indications: Lymphoma | T-Cell Lymphoma | T-Cell Peripheral Lymphoma | Oncology Unspecified
Known Adverse Events: Anemia
Company: TopoTarget A/S
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Germany, Hungary, Italy, Korea, Poland, Spain, Taiwan, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Oncology Solid Tumor Unspecified|T-Cell Peripheral Lymphoma
Phase 2: Uveal Melanoma
Phase 1: Breast Cancer|Oncology Hematological Unspecified|Ovarian Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BELCAP | P3 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2030-10-11 |
|
| CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
|
| SPI-BEL-301 | P3 |
Unknown Status |
T-Cell Peripheral Lymphoma |
2028-03-31 |
|
| MCC-20955 | P2 |
Recruiting |
Uveal Melanoma |
2025-09-01 |